Hepatocarcinogenesis: hepatitis viruses and altered tumor suppressor gene function

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are leading causes of hepatocellular carcinoma (HCC).
• Distinct mechanisms govern the initiation of HCC by HBV and HCV infections.
• Understanding these divergent and convergent pathways is crucial for developing targeted therapies.

Purpose of the Study:

• To delineate the differing initiation processes of HBV- and HCV-associated HCC.
• To identify common pathways in the later stages of hepatocarcinogenesis.
• To explore the role of tumor suppressor genes, such as p53 and RB, in HCC development.

Main Methods:

• Comparative analysis of HBV and HCV infection timelines and viral integration patterns.
• In vitro studies investigating viral protein interactions with oncogenes and tumor suppressors.
• Examination of p53 and RB gene mutation prevalence in HBV- and HCV-associated HCC tissues.

Main Results:

• HBV-associated HCC typically initiates early in life with HBV-DNA integration and potential oncogene transactivation.
• HCV-associated HCC often develops after adult-acquired infection, with no evidence of viral integration or transactivating proteins.
• Both HBV and HCV contribute to HCC through chronic inflammation, cirrhosis, and regenerative processes (tumor promotion).
• p53 tumor suppressor gene mutations are prevalent (30-50%) in both HBV- and HCV-associated HCC, increasing with tumor progression.
• RB gene abnormalities are also frequently observed in HCC, particularly in tumors with p53 mutations.

Conclusions:

• HBV and HCV exhibit distinct early-stage HCC initiation mechanisms but converge in later stages.
• Chronic inflammation, cirrhosis, and p53/RB pathway alterations are common contributors to HCC progression regardless of the initial viral cause.
• Further research is needed to elucidate the role of viral protein binding in p53 inactivation and HCC development.